vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $57.2M, roughly 1.6× Vanda Pharmaceuticals Inc.). HIVE Digital Technologies Ltd. runs the higher net margin — -98.1% vs -246.8%, a 148.7% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 7.6%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 9.8%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
HIVE vs VNDA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $57.2M |
| Net Profit | $-91.3M | $-141.2M |
| Gross Margin | -27.1% | — |
| Operating Margin | — | -70.5% |
| Net Margin | -98.1% | -246.8% |
| Revenue YoY | 218.6% | 7.6% |
| Net Profit YoY | -234.0% | -2774.3% |
| EPS (diluted) | $-0.38 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.1M | $57.2M | ||
| Q3 25 | $87.3M | $56.3M | ||
| Q2 25 | $45.6M | $52.6M | ||
| Q1 25 | — | $50.0M | ||
| Q4 24 | $29.2M | $53.2M | ||
| Q3 24 | $22.6M | $47.7M | ||
| Q2 24 | $32.2M | $50.5M | ||
| Q1 24 | — | $47.5M |
| Q4 25 | $-91.3M | $-141.2M | ||
| Q3 25 | $-15.8M | $-22.6M | ||
| Q2 25 | $35.0M | $-27.2M | ||
| Q1 25 | — | $-29.5M | ||
| Q4 24 | $68.2M | $-4.9M | ||
| Q3 24 | $80.0K | $-5.3M | ||
| Q2 24 | $-18.3M | $-4.5M | ||
| Q1 24 | — | $-4.1M |
| Q4 25 | -27.1% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | -13.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -43.7% | — | ||
| Q3 24 | -66.1% | — | ||
| Q2 24 | -7.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -70.5% | ||
| Q3 25 | — | -55.6% | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -82.0% | ||
| Q4 24 | — | -19.3% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | — | -20.1% | ||
| Q1 24 | — | -19.5% |
| Q4 25 | -98.1% | -246.8% | ||
| Q3 25 | -18.1% | -40.1% | ||
| Q2 25 | 76.8% | -51.7% | ||
| Q1 25 | — | -58.9% | ||
| Q4 24 | 233.2% | -9.2% | ||
| Q3 24 | 0.4% | -11.2% | ||
| Q2 24 | -56.7% | -9.0% | ||
| Q1 24 | — | -8.7% |
| Q4 25 | $-0.38 | $-2.40 | ||
| Q3 25 | $-0.07 | $-0.38 | ||
| Q2 25 | $0.18 | $-0.46 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | $0.52 | $-0.09 | ||
| Q3 24 | $0.00 | $-0.09 | ||
| Q2 24 | $-0.17 | $-0.08 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $559.3M | $327.2M |
| Total Assets | $624.0M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $84.9M | ||
| Q3 25 | — | $70.0M | ||
| Q2 25 | — | $81.0M | ||
| Q1 25 | — | $111.8M | ||
| Q4 24 | $40.5M | $102.3M | ||
| Q3 24 | $31.7M | $100.5M | ||
| Q2 24 | — | $103.0M | ||
| Q1 24 | — | $125.2M |
| Q4 25 | $559.3M | $327.2M | ||
| Q3 25 | $624.6M | $466.0M | ||
| Q2 25 | $560.5M | $486.3M | ||
| Q1 25 | — | $511.4M | ||
| Q4 24 | $430.9M | $538.5M | ||
| Q3 24 | $275.5M | $541.2M | ||
| Q2 24 | $268.6M | $542.5M | ||
| Q1 24 | — | $544.0M |
| Q4 25 | $624.0M | $488.9M | ||
| Q3 25 | $693.0M | $601.1M | ||
| Q2 25 | $628.7M | $624.7M | ||
| Q1 25 | — | $631.9M | ||
| Q4 24 | $478.6M | $656.2M | ||
| Q3 24 | $334.7M | $645.1M | ||
| Q2 24 | — | $651.4M | ||
| Q1 24 | — | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.0M | $-29.4M | ||
| Q3 25 | $-10.6M | $-31.6M | ||
| Q2 25 | $10.2M | $-15.3M | ||
| Q1 25 | — | $-33.1M | ||
| Q4 24 | $-28.5M | $-1.8M | ||
| Q3 24 | $-2.2M | $-14.6M | ||
| Q2 24 | $-4.4M | $-6.9M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | $-55.5M | $-2.0M | ||
| Q3 24 | $-34.7M | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | -189.9% | -3.8% | ||
| Q3 24 | -153.4% | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | 92.5% | 0.4% | ||
| Q3 24 | 143.9% | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIVE
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
